A Trial in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

About this Study

The optimal treatment for PH+ ALL has not yet been determined.  There is now general consensus among North American and European Childhood ALL treatment groups that Ph+ ALL patients with a favorable early response to the combination of chemotherapy and tyrosine kinase inhibitor (TKI) treatment can be treated without hematopoeitic stem cell transplant in first complete remission.  Two different chemotherapy backbones have been used in combination with TKI therapy in recent North American and European pediatric Ph+ ALL trials.  This study will compare those two chemotherapy backbones with the use of imatinib as TKI therapy to determine which chemotherapy backbone will have a higher disease free survival.

Sponsor Protocol ID:AALL1631
IRB Number:2017-0239
Actively Enrolling
Phase 3
May 28, 2019
Eligibility Criteria
1 year old
21 years old
Both Male and Female

Inclusion CriteriaBoth men and women of all races and ethnic groups are eligible for this study.

Exclusion Criteria
  • Known history of chronic myelogenous leukemia. 
  • ALL developing after a previous cancer treated with cytotoxic chemotherapy. 
  • Active, uncontrolled infection or active systemic illness that requires ongoing vasopressor support or mechanical ventilation. 
  • Down syndrome. 
  • Pregnancy and Breast Feeding. 

Categories Click category to view its trials.
Participating Locations
Batson Children’s Hospital
Contact Information
Contact Name: Rachel Lowery
Phone Number: 601-984-5224
Email: rlowery@umc.edu
Principal Investigator:Collier, Anderson B, M.D.
How to participate in our Clinical Trials